The emergence of COVID-19 almost five years ago forced us all to face the realities of containing and mitigating a highly transmissible, deadly pandemic.
The field of biologics is vast and growing, with tremendous potential to improve patients’ lives and public health.
The COVID-19 pandemic has presented unprecedented challenges around the world, including to national public health systems and the international biopharmaceutical industry.
COVID-19 is transforming our ways of thinking about the development, manufacture and delivery of critical medicines to patients around the world.
During the COVID-19 pandemic, we have become acutely aware of how precious time is and the potential repercussions of delays or inefficiencies.
The spread of COVID-19 has been a wake-up call to the world about dangers posed by over-reliance on single-country sources in the global medicine supply chain.
Innovations in biotherapeutic medicines are advancing at an unprecedented pace and offer great promise for improving outcomes for patients.
What happens when patients who receive a trusted treatment start experiencing adverse reactions? And what can be done to help prevent it from reoccurring?
Show 11 More